Odd Terje Brustugun

Odd Terje Brustugun is a Professor II in the Department of Oncology at the University of Oslo, Faculty of Medicine, with a clinical affiliation at the Section of Oncology, Drammen Hospital. He is actively engaged in clinical and translational research in lung cancer, focusing on treatment optimization, biomarker discovery, and population-based oncology studies.

His research interests include lung cancer, thoracic oncology, radiotherapy, targeted therapy, immunotherapy, cancer epidemiology, and health services research. His work bridges clinical practice with population-level data analysis, particularly in Norwegian cohorts.

The most recent articles reflect a strong focus on real-world treatment outcomes, biomarker-driven therapies (e.g., EGFR, ALK, PD-L1), resistance mechanisms to tyrosine kinase inhibitors like osimertinib, and epidemiological trends in lung cancer diagnosis and survival. His publications frequently appear in high-impact journals such as Journal of Thoracic Oncology, Lung Cancer, and Acta Oncologica.

Scientific Contributions:

• Published extensively on thoracic radiotherapy regimens in SCLC.
• Investigated compliance with cancer patient pathways in Norway.
• Explored molecular mechanisms of drug resistance in NSCLC.
• Conducted nationwide studies on lung cancer survival and treatment patterns.

He has advised or collaborated with multiple researchers and is involved in national and international oncology initiatives. His work contributes significantly to precision medicine and improving lung cancer outcomes in clinical practice.

Brustugun is part of the Lung cancer control strategies (LC-CONTROL) research project, indicating ongoing engagement in public health-oriented oncology research. His clinical and academic roles are integrated within the Norwegian healthcare and university system, particularly through Oslo University Hospital and the University of Oslo.